pharma · No medical condition. · Generalized Myasthenia Gravis
Anaxis Pharma
Lacuna Pharma Pty Ltd
Anaxis Pharma clinical programs — 198 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Melbourne, AU
- Founded
- 2017
- Employees
- 7
- Programs
- 642
- Drugs
- 673
- Patents
- 0
Anaxis Pharma projects
198 ClinicalTrials.gov programs sponsored by Anaxis Pharma.
Anaxis Pharma has 198 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
bimekizumab
Lacuna Pharma Pty Ltd
Psoriatic Arthritis
1 trial -
bimekizumab
Lacuna Pharma Pty Ltd
Axial Spondyloarthritis
1 trial -
bimekizumab
Lacuna Pharma Pty Ltd
Hidradenitis Suppurativa
1 trial -
bimekizumab
Lacuna Pharma Pty Ltd
Hidradenitis Suppurativa
1 trial -
sotatercept, PL1 - Powder for injection
Lacuna Pharma Pty Ltd
Therapeutic confirmatory (phase III)
1 trial -
sotatercept, sotatercept
Lacuna Pharma Pty Ltd
Pulmonary Arterial Hypertension (PAH)
1 trial
Frequently asked questions
How many clinical projects does Anaxis Pharma have?
198 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.